nChroma

nChroma Bio is a clinical-stage genetic medicines company formed in December 2024 through the strategic merger of Chroma Medicine and Nvelop Therapeutics. The company is developing engineered epigenetic silencers — a new class of single-dose genomic medicines that harness epigenetics, the body's innate mechanism for gene regulation, to treat primary immunodeficiencies and other severe genetic diseases. nChroma combines Chroma Medicine's best-in-class epigenetic editing technologies with Nvelop's next-generation in vivo targeted delivery platforms, including lipid nanoparticles (LNPs), to enable durable gene silencing without permanent DNA cuts. The company takes a disease-first approach to therapeutic design, targeting conditions where existing gene therapies face significant limitations. Headquartered in Cambridge, Massachusetts, nChroma is led by CEO Jeffrey Walsh and backed by top-tier investors including F-Prime Capital, Atlas Venture, Newpath Partners, and Cormorant Asset Management. The company secured $75 million in financing alongside the merger to accelerate its pipeline toward the clinic.